Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Metastatic Breast Cancer Clinical Trial

Official title:

A Phase II Open-Label Trial to Evaluate the Efficacy and Toxicity of Tarceva (Erlotinib) in Women With Metastatic, Hormone Receptor Negative and Her2-Negative Breast Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00597597
• Other study ID #: OSI-TAR-721 | L06112402
• Status: Terminated
• Phase: Phase 2
• Start date: April 2007
• Est. completion date: April 2011

Study information

• Verified date: May 2023
• Source: Rush University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this trial is to determine the activity of erlotinib in a rationally selected population of women with ER-negative, PR-negative, HER2/neu-negative, EGFR-positive breast cancer. If erlotinib is shown to have activity, this could identify a form of targeted therapy for this specific subset of breast cancer patients. In addition, it may identify a subset of breast cancer patients with tumors that overexpress EGFR in whom other EGFR targeted therapies could warrant further testing.

Description:

This is a Phase II, open-label, single institution trial of treatment with single agent erlotinib. The purpose of the research is to determine the effects erlotinib has on the breast cancer tumors in women with metastatic hormone receptor negative and HER2-negative breast cancer. The Federal Drug Administration (FDA) has approved erlotinib, also known as Tarceva, for the treatment of locally advanced and metastatic non-small cell lung cancer. To qualify for the trial, subjects must have histologically confirmed, incurable, locally advanced or metastatic breast cancer that is ER-negative, PR-negative, Her2/neu-negative and EGFR-positive. Subjects must have measurable disease. They must have received less than or equal to 1 chemotherapeutic agent in the metastatic setting. The target accrual is 43 subjects. Initially, 18 subjects will be accrued. If at least 3 subjects are progression-free at 4 months, accrual will continue to a maximum of 43 subjects. Subject eligibility will be evaluated during a screening period of 4 weeks. During the treatment period, subjects will receive single agent erlotinib, 150mg/day. Subjects will receive the first dose of erlotinib on Day 0, within 7 days of registration. Efficacy will be assessed by radiographic tumor assessment or photographic documentation. Safety will be assessed by the recording of adverse events and laboratory test results. Subjects with documented progressive disease will be discontinued from treatment and will be followed for survival information every 2 months until death, lost to follow-up or study termination.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: April 2011
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Verbal and written informed consent to participate in the study.

2. Women greater than or equal to 18 years of age.

3. Histologically documented metastatic or locally advanced, incurable breast cancer with a tumor block available

4. Less than or equal to 1 prior chemotherapy for metastatic or locally unresectable disease.

5. Prior treatment with anthracycline and taxane chemotherapy, either in the adjuvant or metastatic setting

6. Measurable disease on CT or PET scan or physical exam Disease at a previously irradiated site is considered measurable if there is clear evidence of disease progression following radiation therapy.

7. ER-negative, PR-negative and HER2-neu-negative. Estrogen and progesterone status will be defined by immunohistochemistry. Her2/neu status will be considered negative if the ratio of the number of copies of the Her2/neu gene to the centromeric probe for chromosome 17 is approximately 1. This will be done by FISH (fluorescent in-situ hybridization) testing.

8. EGFR-positive defined as strong membrane staining in greater than 10% of tumor cells by immuno-histochemistry (Dako).

9. Pre- or post-menopausal.

10. ECOG performance status of 0 - 2.

11. Life expectancy of greater than or equal to 3 months.

12. Use of barrier contraceptive methods in women of childbearing potential.

13. Ability to comply with study and follow-up procedures.

Exclusion Criteria:

1. Pleural effusions or blastic bone lesions as the only manifestations of the current metastatic breast cancer.

2. Other primary malignancies within 5 years except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer.

3. Symptomatic or untreated brain metastases. Subjects are eligible if they are neurologically stable after treatment for brain metastases and have been off steroids for greater than or equal to 4 weeks.

4. Radiotherapy, immunotherapy, hormonal therapy or chemotherapy within 21 days prior to registration.

5. Prior treatment with an agent that targets the EGFR or the EGFR-specific tyrosine kinase activity.

6. Unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to Day 0, or serious cardiac arrhythmias requiring medication.

7. Major surgery, biopsy of a parenchymal organ, or significant traumatic injury occurring within 21 days prior to Day 0.

8. History of other diseases, metabolic dysfunction, physical examinations findings, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk from treatment complications.

9. Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease.

10. Pregnancy or lactation. A negative serum or urine pregnancy test is required for women of child-bearing potential during screening and within 7 - 10 days of Day 1 of Cycle 1 of erlotinib (Tarcevo®)administration. Men and premenopausal women of child bearing potential will follow an approved, medically accepted birth control regimen while taking erlotinib and for 30 days following the last dose of study drug.

11. Active infection requiring parenteral antibiotics.

12. Any of the following abnormal baseline hematologic values:

• Granulocyte count less than or equal to 1500/µL
• Platelet count less than or equal to 100,000/µL
• Hemoglobin less than or equal to 9g/dl (transfusion permitted)

13. Any of the following abnormal baseline liver function tests:

• Serum bilirubin greater than or equal to 1.5x upper limit of normal (ULN)
• Serum ALT and AST greater than or equal to 2.5x ULN (greater than 5x ULN if due to liver metastases)
• Alkaline phosphatase greater than or equal to 2.5x ULN (greater than 4x ULN if due to liver or bone metastases)

14. Other baseline laboratory values:

• Serum creatinine greater than or equal to 1.5x ULN or creatinine clearance less than or equal to 60mL/min
• Uncontrolled hypercalcemia (greater than 11.5mg/dL)

Related Conditions & MeSH terms

• Breast Neoplasms
• Metastatic Breast Cancer

Intervention

Drug:
• Erlotinib
During the treatment period, subjects will receive single agent erlotinib, 150mg/day.

Locations

Country	Name	City	State
United States	Rush University Medical Center Division of Hematology/Oncology	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Rush University Medical Center

Country where clinical trial is conducted

United States, 

References & Publications (1)

J Clin Oncol 29, 2011 (suppl 27; abstr 296)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Primary Objective of the Study is Progression Free Survival.	From the Day of Initial Treatment (Day 0) Until Documented Disease Progression or Death.	From the Day of Initial Treatment (Day 0) Until Documented Disease Progression or Death, whichever came first, assessed up to 6 months.
Secondary	Overall Response Rate, Consisting of Complete and Partial Responses According to RECIST Criteria	Overall response rate, consisting of complete and partial responses according to RECIST criteria "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR."	every 8 weeks, up to 6 months
Secondary	Clinical Benefit, Consisting of Complete and Partial Responses, and Stable Disease for Six Months	We measured the clinical benefit, consisting of complete and partial responses, and stable disease for six months	very 8 weeks, up to 6 months
Secondary	Duration of Objective Response	Objective response is defined as complete or partial response	every 8 weeks, up to 6 months
Secondary	Safety of Erlotinib	Number of Participants With Adverse Events	2 years
Secondary	Number of Participants With Rash	We evaluated the number of Participants with Rash	every 8 weeks, up to 6 months